Year: 2017
Type: article
Study design: Observational Study
Abstract: AIMS/HYPOTHESIS: The aims of this study were to evaluate systematically the predictive power of comprehensive metabolomics profiles in predicting the future risk of type 2 diabetes, and to identify a panel of the most predictive metabolic markers. METHODS: We applied an unbiased systems medicine approach to mine metabolite combinations that provide added value in predicting the future incidence of type 2 diabetes beyond known risk factors. We performed mass spectrometry-based targeted, as well as global untargeted, metabolomics, measuring a total of 568 metabolites, in a Finnish cohort of 543 non-diabetic individuals from the Botnia Prospective Study, which included 146 individuals who progressed to type 2 diabetes by the end of a 10 year follow-up period. Multivariate logistic regression was used to assess statistical associations, and regularised least-squares modelling was used to perform machine learning-based risk classification and marker selection. The predictive performance of the machine learning models and marker panels was evaluated using repeated nested cross-validation, and replicated in an independent French cohort of 1044 individuals including 231 participants who progressed to type 2 diabetes during a 9 year follow-up period in the DESIR (Data from an Epidemiological Study on the Insulin Resistance Syndrome) study. RESULTS: Nine metabolites were negatively associated (potentially protective) and 25 were positively associated with progression to type 2 diabetes. Machine learning models based on the entire metabolome predicted progression to type 2 diabetes (area under the receiver operating characteristic curve, AUC = 0.77) significantly better than the reference model based on clinical risk factors alone (AUC = 0.68; DeLong's p = 0.0009). The panel of metabolic markers selected by the machine learning-based feature selection also significantly improved the predictive performance over the reference model (AUC = 0.78; p = 0.00019; integrated discrimination improvement, IDI = 66.7%). This approach identified novel predictive biomarkers, such as α-tocopherol, bradykinin hydroxyproline, X-12063 and X-13435, which showed added value in predicting progression to type 2 diabetes when combined with known biomarkers such as glucose, mannose and α-hydroxybutyrate and routinely used clinical risk factors. CONCLUSIONS/INTERPRETATION: This study provides a panel of novel metabolic markers for future efforts aimed at the prevention of type 2 diabetes.
Source: Diabetologia
Institutions: University of Helsinki, Institute for Molecular Medicine Finland, VTT Technical Research Centre of Finland, Metabolon (United States), Centre National de la Recherche Scientifique, The University of Queensland, Université de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, (Epi)génomique fonctionnelle métabolique et des dysfonctions dans le diabète de type 2 et des maladies associées, Institute for Molecular Bioscience, Hammersmith Hospital, Imperial College London, Lund University, Université Paris-Sud, Inserm, Université de Versailles Saint-Quentin-en-Yvelines, Université Paris-Saclay, Centre de recherche en Epidémiologie et Santé des Populations, Helsinki University Hospital, University of Turku
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,490
Awards: Genetics and epigenetics of Type 2 Diabetes physiology, G2178648417, General and targeted approaches to unravel the molecular causes of type 2 diabetes, G3479052434, G3533229685, G4347981189, Coupled fluid-solid numerical modelling for deep-water and far-offshore floating wind turbines using an adaptive finite element method, "THE EUROPEAN ACADEMIC AND INDUSTRY NETWORK FOR INNOVATIVE MARITIME TRAINING, EDUCATION AND R&D", G6865802051, Plate forme Lilloise de séquençage du génome humain pour une médecine personnalisée, G7376787254
OpenAlex ID: W2623957926
